Skip to main content

Enteral Feeding Intolerance

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Theravance Biopharma
1 program
1
TD-8954Phase 1/21 trial
Active Trials
NCT01953081Completed13Est. Oct 2014
Avanos Medical
Avanos MedicalBelgium - Zavantem
1 program
Enteric TubeN/A1 trial
Active Trials
NCT04241146Completed52Est. Nov 2019
Takeda
TakedaTOKYO, Japan
1 program
TD-8954PHASE_1_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Theravance BiopharmaTD-8954
Avanos MedicalEnteric Tube

Clinical Trials (2)

Total enrollment: 65 patients across 2 trials

A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Start: Jan 2014Est. completion: Oct 201413 patients
Phase 1/2Completed

Optimal Feeding Tube Placement

Start: Jan 2018Est. completion: Nov 201952 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.